Eclipse TMR Holmium Laser System
by Cryolife, Inc. PMA
Active
PMA P970029
Overview
The Eclipse TMR Holmium Laser System is a medical device designed for transmyocardial revascularization (TMR). It uses a holmium laser to create channels in the myocardium to improve blood flow in ischemic heart tissue.
It is indicated for use in stable patients with Canadian Cardiovascular Society Class 4 angina refractory to medical treatment and secondary to coronary artery atherosclerosis with reversible ischemia not amenable to direct revascularization. The system received FDA PMA approval (P970029) and is manufactured by Cryolife, Inc. in Kennesaw, GA.
Regulatory status
| Region | Authorization | Number | Date | Status |
|---|---|---|---|---|
| United States | FDA PMAAPPR | NumberP970029 | Date11 Feb 1999 | StatusActive |
Coverage
- Active
- Expiring
- Withdrawn
- Listed
- Not known
- Not covered
United States — FDA PMA Active
Recalls
No FDA recalls on record, checked 6 Oct 2026.
Specification
- Trade Name
- Tmr Holmium Laser System
- Generic Name
- SYSTEM, LASER, TRANSMYOCARDIAL REVASCULARIZATION
- PMA Number
- FDA Product Code
- MNO
- Device Class
- Class III
- Advisory Committee
- Cardiovascular
- FDA Decision
- APPR Approved
Other devices from Cryolife, Inc.
Questions
What is the Eclipse TMR Holmium Laser System used for?
The Eclipse TMR Holmium Laser System is used for transmyocardial revascularization to treat stable patients with refractory angina (Canadian Cardiovascular Society Class 4) due to coronary artery atherosclerosis with reversible ischemia not suitable for direct revascularization, as stated in the approval documentation.
Who manufactures the Eclipse TMR Holmium Laser System and where are they located?
The Eclipse TMR Holmium Laser System is manufactured by Cryolife, Inc., located at 1655 Roberts Blvd. NW, Kennesaw, GA 30144, as specified in the device data.
What regulatory authorization does the Eclipse TMR Holmium Laser System have?
The Eclipse TMR Holmium Laser System has FDA PMA (Premarket Approval) authorization, with PMA number P970029, approved on February 11, 1999, as indicated in the AUTHORIZATIONS and PMA_NUMBER fields.